Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free NNNN Stock Alerts

Anbio Biotechnology (NNNN) Financials

Anbio Biotechnology logo
$26.94 +1.87 (+7.46%)
Closing price 04:00 PM Eastern
Extended Trading
$26.25 -0.69 (-2.56%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Anbio Biotechnology

Annual Income Statements for Anbio Biotechnology

This table shows Anbio Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 10 2.25 2.37 6.40
Consolidated Net Income / (Loss)		 10 2.25 2.37 6.40
Net Income / (Loss) Continuing Operations		 10 2.25 2.37 6.40
Total Pre-Tax Income 		10 2.25 2.37 6.40
Total Operating Income		 10 1.96 2.00 5.77
Total Gross Profit		 13 3.36 5.89 7.54
Total Revenue		 24 6.71 8.19 8.65
Operating Revenue		 24 6.71 8.19 8.65
Total Cost of Revenue		 11 3.35 2.30 1.10
Operating Cost of Revenue		 11 3.35 2.30 1.10
Total Operating Expenses		 2.37 1.40 3.89 1.78
Selling, General & Admin Expense		 2.17 1.27 3.44 1.57
Research & Development Expense		 0.20 0.13 0.45 0.20
Total Other Income / (Expense), net		 -0.18 0.29 0.38 0.64
Interest & Investment Income		 0.04 0.17 0.34 0.14
Other Income / (Expense), net		 -0.22 0.13 0.04 0.49
Income Tax Expense		 0.00 0.00 0.00 0.00
Basic Earnings per Share		 $100,112.00 $0.11 $0.06 $0.15
Weighted Average Basic Shares Outstanding		 100.00 21.44M 42.29M 43.67M
Diluted Earnings per Share		 $100,112.00 $0.11 $0.06 $0.15
Weighted Average Diluted Shares Outstanding		 - - 142.29M 143.89M
Weighted Average Basic & Diluted Shares Outstanding		 - - 142.29M 143.89M

Quarterly Income Statements for Anbio Biotechnology

No quarterly income statements for Anbio Biotechnology are available.

Annual Cash Flow Statements for Anbio Biotechnology

This table details how cash moves in and out of Anbio Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.92 2.59 2.07 -3.99
Net Cash From Operating Activities		 4.45 0.90 2.08 -6.74
Net Cash From Continuing Operating Activities		 4.45 0.90 2.08 -6.74
Net Income / (Loss) Continuing Operations		 10 2.25 2.37 6.40
Consolidated Net Income / (Loss)		 10 2.25 2.37 6.40
Amortization Expense		 0.01 0.01 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 -0.04 -0.16 -0.34 0.07
Changes in Operating Assets and Liabilities, net		 -5.53 -1.20 0.04 -13
Net Cash From Investing Activities		 -1.53 1.73 0.34 -4.20
Net Cash From Continuing Investing Activities		 -1.53 1.73 0.34 -4.20
Purchase of Investments		 -16 -19 -35 -19
Sale and/or Maturity of Investments		 15 20 36 15
Net Cash From Financing Activities		 0.00 -0.04 -0.34 6.95
Net Cash From Continuing Financing Activities		 0.00 -0.04 -0.34 6.95
Repurchase of Common Equity		 0.00 -0.04 -0.34 -0.28
Issuance of Common Equity		 - 0.00 0.00 7.23

Quarterly Cash Flow Statements for Anbio Biotechnology

No quarterly cash flow statements for Anbio Biotechnology are available.

Annual Balance Sheets for Anbio Biotechnology

This table presents Anbio Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 19 30
Total Current Assets		 16 19 30
Cash & Equivalents		 9.69 12 7.77
Short-Term Investments		 - 0.00 4.13
Accounts Receivable		 1.88 1.06 3.66
Prepaid Expenses		 4.18 0.03 0.61
Other Current Assets		 - 5.68 14
Plant, Property, & Equipment, net		 0.00 0.00 0.00
Total Noncurrent Assets		 0.06 0.39 0.00
Other Noncurrent Operating Assets		 0.04 0.39 0.00
Total Liabilities & Shareholders' Equity		 16 19 30
Total Liabilities		 0.99 1.73 0.09
Total Current Liabilities		 0.99 1.73 0.09
Accounts Payable		 0.83 1.63 0.00
Other Current Liabilities		 0.17 0.10 0.09
Total Noncurrent Liabilities		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 17 30
Total Preferred & Common Equity		 15 17 30
Total Common Equity		 15 17 30
Common Stock		 0.02 0.02 6.58
Retained Earnings		 15 17 24

Quarterly Balance Sheets for Anbio Biotechnology

No quarterly balance sheets for Anbio Biotechnology are available.

Annual Metrics And Ratios for Anbio Biotechnology

This table displays calculated financial ratios and metrics derived from Anbio Biotechnology's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00
Growth Metrics		 - - - -
Revenue Growth		 0.00% -71.49% 21.95% 5.64%
EBITDA Growth		 0.00% -78.96% -3.10% 207.64%
EBIT Growth		 0.00% -79.07% -2.54% 207.64%
NOPAT Growth		 0.00% -80.77% 1.76% 189.06%
Net Income Growth		 0.00% -77.49% 5.29% 169.86%
EPS Growth		 0.00% -100.00% -46.67% 162.50%
Operating Cash Flow Growth		 0.00% -79.81% 131.57% -423.93%
Free Cash Flow Firm Growth		 0.00% 0.00% 153.49% -516.15%
Invested Capital Growth		 0.00% 0.00% 5.85% 236.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 53.36% 50.07% 71.90% 87.24%
EBITDA Margin		 42.40% 31.29% 24.87% 72.41%
Operating Margin		 43.30% 29.22% 24.38% 66.70%
EBIT Margin		 42.37% 31.11% 24.87% 72.41%
Profit (Net Income) Margin		 42.52% 33.58% 28.99% 74.06%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.34% 107.92% 116.58% 102.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 76.44% 37.79% 48.70%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 70.39% 34.27% 43.33%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -46.02% -22.96% -21.66%
Return on Equity (ROE)		 0.00% 30.42% 14.83% 27.05%
Cash Return on Invested Capital (CROIC)		 0.00% -123.56% 32.11% -59.58%
Operating Return on Assets (OROA)		 0.00% 13.21% 11.72% 25.47%
Return on Assets (ROA)		 0.00% 14.25% 13.66% 26.05%
Return on Common Equity (ROCE)		 0.00% 30.42% 14.83% 27.05%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 10 1.96 2.00 5.77
NOPAT Margin		 43.30% 29.22% 24.38% 66.70%
Net Nonoperating Expense Percent (NNEP)		 0.00% 6.04% 3.52% 5.37%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.23% 11.61% 19.13%
Cost of Revenue to Revenue		 46.64% 49.93% 28.10% 12.76%
SG&A Expenses to Revenue		 9.21% 18.85% 41.98% 18.20%
R&D to Revenue		 0.85% 2.01% 5.55% 2.33%
Operating Expenses to Revenue		 10.06% 20.86% 47.53% 20.53%
Earnings before Interest and Taxes (EBIT)		 9.98 2.09 2.04 6.26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 9.98 2.10 2.04 6.26
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.54 0.47 143.49
Price to Tangible Book Value (P/TBV)		 0.00 0.54 0.47 143.49
Price to Revenue (P/Rev)		 0.34 1.19 0.98 500.39
Price to Earnings (P/E)		 0.80 3.55 3.37 675.70
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 125.14% 28.17% 29.66% 0.15%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 236.38
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 499.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 689.12
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 689.12
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 748.11
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.65 -0.67 -0.50
Leverage Ratio		 0.00 1.07 1.09 1.04
Compound Leverage Factor		 0.00 1.15 1.27 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 8.12 5.90 29,559.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 15.86 10.71 344.31
Quick Ratio		 0.00 11.65 7.41 177.12
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.17 1.70 -7.06
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 556.18 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 556.18 0.00 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.42 0.47 0.35
Accounts Receivable Turnover		 0.00 3.56 5.55 3.66
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 4.05 1.88 0.00
Days Sales Outstanding (DSO)		 0.00 102.50 65.77 99.64
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 90.09 194.61 0.00
Cash Conversion Cycle (CCC)		 0.00 12.41 -128.84 99.64
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 5.13 5.43 18
Invested Capital Turnover		 0.00 2.62 1.55 0.73
Increase / (Decrease) in Invested Capital		 0.00 5.13 0.30 13
Enterprise Value (EV)		 0.00 -1.69 -3.76 4,315
Market Capitalization		 8.00 8.00 8.00 4,327
Book Value per Share		 $0.00 $0.69 $0.41 $0.69
Tangible Book Value per Share		 $0.00 $0.69 $0.41 $0.69
Total Capital		 0.00 15 17 30
Total Debt		 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 0.00 -9.69 -12 -12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 5.07 5.04 18
Debt-free Net Working Capital (DFNWC)		 0.00 15 17 30
Net Working Capital (NWC)		 0.00 15 17 30
Net Nonoperating Expense (NNE)		 0.18 -0.29 -0.38 -0.64
Net Nonoperating Obligations (NNO)		 0.00 -9.69 -12 -12
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 75.52% 61.61% 211.10%
Debt-free Net Working Capital to Revenue		 0.00% 219.85% 205.30% 348.74%
Net Working Capital to Revenue		 0.00% 219.85% 205.30% 348.74%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.06 $0.15
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 42.29M 43.67M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.06 $0.15
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 142.29M 143.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 142.29M 143.89M
Normalized Net Operating Profit after Tax (NOPAT)		 7.14 1.37 1.40 4.04
Normalized NOPAT Margin		 30.31% 20.45% 17.06% 46.69%
Pre Tax Income Margin		 42.52% 33.58% 28.99% 74.06%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 1,247.27 0.00 0.00 0.00
NOPAT to Interest Expense		 1,274.61 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 1,247.27 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 1,274.61 0.00 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 1.90% 14.52% 4.41%

Quarterly Metrics And Ratios for Anbio Biotechnology

No quarterly metrics and ratios for Anbio Biotechnology are available.


Financials Breakdown Chart

Anbio Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Anbio Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Anbio Biotechnology's net income appears to be on a downward trend, with a most recent value of $6.40 million in 2025, falling from $10.01 million in 2022. The previous period was $2.37 million in 2024. See Anbio Biotechnology's forecast for analyst expectations on what's next for the company.

Anbio Biotechnology's total operating income in 2025 was $5.77 million, based on the following breakdown:
  • Total Gross Profit: $7.54 million
  • Total Operating Expenses: $1.78 million

Over the last 3 years, Anbio Biotechnology's total revenue changed from $23.54 million in 2022 to $8.65 million in 2025, a change of -63.3%.

Anbio Biotechnology's total liabilities were at $87.84 thousand at the end of 2025, a 94.9% decrease from 2024, and a 91.2% decrease since 2023.

In the past 2 years, Anbio Biotechnology's cash and equivalents has ranged from $7.77 million in 2025 to $11.76 million in 2024, and is currently $7.77 million as of their latest financial filing in 2025.

Over the last 3 years, Anbio Biotechnology's book value per share changed from 0.00 in 2022 to 0.69 in 2025, a change of 69.1%.


Related Companies

Financial statements for NASDAQ:NNNN last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel